Mounjaro Drops: The Myth, the Medicine, and What's Actually Licensed in the UK

The biggest misconception: "drops" are just a different format of the same drug

A question our prescribers hear most weeks runs something like: "I've seen Mounjaro drops online, are they the same thing, just easier to take?" The short answer is no. Tirzepatide's pharmacology depends on subcutaneous delivery. The molecule is a large peptide that enzymes in the digestive tract break down before it can reach the bloodstream in meaningful concentrations. That is precisely why the licensed KwikPen delivers the medicine beneath the skin, bypassing the gut entirely.

Products marketed as tirzepatide drops or liquid tirzepatide have not cleared the MHRA's authorisation process for weight management. They have not undergone the pharmacokinetic studies that would be required to demonstrate equivalent absorption, efficacy or safety via an oral route. Calling a liquid "Mounjaro drops" borrows the brand's credibility without carrying any of its evidence base. Our tirzepatide overview covers exactly how the authorised medicine works and what the clinical trial programme established.

If you are curious whether any oral GLP-1 options do exist in the UK, oral semaglutide tablets (Wegovy tablets) received MHRA approval in June 2026, but these are a different active ingredient and a different product entirely, not a drop-format equivalent of Mounjaro.

Why unlicensed "drops" sold online are a red flag, not a shortcut

The MHRA has been explicit about the risks of obtaining weight-loss medicines from unverified online sellers. Enforcement operations through 2024 and 2025 uncovered counterfeit pens containing insulin rather than the stated active ingredient, with hospitalisations resulting. The same pattern applies to any unregulated format: without independent laboratory testing, a buyer has no way of knowing what is actually in a vial labelled "tirzepatide drops."

The red flags to watch for overlap almost exactly with what characterises the drops market: sellers offering weight-loss medicines without a prescription, pricing dramatically below the reported UK market range, no visible GPhC registration, and no clinical assessment involved. You can verify any online pharmacy in seconds on the GPhC pharmacy register. If a seller is not on it, the medicines they supply are not being dispensed within the UK's regulated framework.

The MHRA's public guidance on GLP-1 medicines makes the position clear: these are Prescription-Only Medicines, assessed case by case by a prescriber. There is no compliant version of "buy drops, no clinical review required." Our explainer on whether tirzepatide drops work goes into more detail on what the evidence actually supports.

What the licensed Mounjaro KwikPen actually involves

For context, here is what a legitimate supply of tirzepatide looks like. Treatment starts at 2.5 mg (a tolerability dose designed to let your body adjust) delivered once a week via a pre-filled pen into the abdomen, thigh or upper arm. The prescriber reviews your suitability first: BMI, any relevant conditions, current medicines, medical history. The pen is stored in the fridge. Each KwikPen contains four weekly doses.

SURMOUNT-1, the pivotal phase 3 trial published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the highest dose over 72 weeks in adults without diabetes. That evidence base was built entirely on subcutaneous delivery. There is no equivalent dataset for a drop formulation, because no such formulation has been put through that process. The Mounjaro information page covers the full licensed picture, including eligibility and what to expect through the titration schedule.

Understanding the cost landscape is a separate question, our Mounjaro cost page explains what private treatment typically involves and what a legitimate price covers, including the clinical assessment that unlicensed sellers omit entirely.

The sensible alternative if injections genuinely put you off

For some people, the appeal of "drops" is straightforward: needles are not for everyone. That instinct is completely understandable. The good news is that the UK now has a licensed non-injection option for weight management. Wegovy tablets (oral semaglutide) were approved by the MHRA on 11 June 2026. They are taken once daily on an empty stomach, first thing in the morning, before food or other medicines. The trial data reported an average weight loss of around 13.6% over 64 weeks versus placebo.

It is worth noting that oral semaglutide is a different active ingredient from tirzepatide, and which option suits a given person is a clinical call, not a preference click. If you are also weighing up how Mounjaro interacts with recreational substances such as MDMA, that is another area where a prescriber conversation is essential before starting treatment. The weight-loss treatment overview sets out what is currently licensed and how the options compare. If you want a prescriber to assess which medicine, if any, is appropriate for you, the starting point is a consultation, and ours is free, reviewed the same day by a named GPhC-registered prescriber, never by software. Speak to our prescribers through our treatment page when you are ready.